drugset / Trial / NCT01006681

Vaccination Against Influenza H1N1 in Rheumatic Diseases

NCT01006681

Phase 2 Unknown 400 enrolled Tel-Aviv Sourasky Medical Center
Non-randomizedSingle-groupOpen-labelPrevention

Summary

The spread of Influenza H1N1 has prompted the development of vaccines against this virus. Immunocompromised patients are at increased risk of developing complications of Influenza H1N1. The efficacy and safety of H1N1 vaccination have not been evaluated in this population of patients.

Timeline

Start
2009-11
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Focetria Vaccine 7.5 ug Intramuscular
Subject Focetria Vaccine 7.5 mg Intramuscular